Palvella Therapeutics (PVLA) Accumulated Expenses (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Accumulated Expenses data on file, last reported at $675000.0 in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $675000.0, down 73.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $675000.0 (down 73.67% YoY), and the FY2025 annual result was $4.4 million, down 20.52% from the prior year.
• Accumulated Expenses declined to $675000.0 in Q1 2026 per PVLA's latest filing, from $4.4 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $12.8 million in Q3 2023 and troughed at $675000.0 in Q1 2026.
• A 5-year average of $4.4 million and a median of $3.5 million in 2024 frame the typical range for Accumulated Expenses.
• On a YoY basis, Accumulated Expenses climbed as much as 292.98% in 2023 and fell as far as 86.75% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $10.7 million in 2022, then slumped by 86.75% to $1.4 million in 2023, then soared by 284.41% to $5.5 million in 2024, then decreased by 20.52% to $4.4 million in 2025, then tumbled by 84.49% to $675000.0 in 2026.
• Business Quant data shows PVLA's Accumulated Expenses at $675000.0 in Q1 2026, $4.4 million in Q4 2025, and $4.6 million in Q3 2025.